Immunotherapy
PD-L1 Inhibitor
Also known as: Anti-PD-L1 therapy, PD-L1 blockade
Definition
A checkpoint inhibitor that blocks the PD-L1 protein on tumor cells, allowing T cells to recognize and attack cancer.
Detailed Explanation
PD-L1 inhibitors target the ligand (PD-L1) rather than the receptor (PD-1). Examples include atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio). They work similarly to PD-1 inhibitors but may have slightly different side effect profiles. Used in lung cancer, bladder cancer, and other malignancies.